Free Trial
→ Why Trump’s “Smart Dollar” could rewrite the rules (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iBio, Inc. stock logo
IBIO
iBio
$0.86
+5.9%		$0.73
$0.56
▼
$6.89
$16.88M0.861.53 million shs977,930 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iBio, Inc. stock logo
IBIO
iBio
-0.94%+2.91%+22.91%-18.04%-58.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iBio, Inc. stock logo
IBIO
iBio
2.3712 of 5 stars		3.50.00.00.04.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iBio, Inc. stock logo
IBIO
iBio
3.00
Buy$5.00482.21% Upside

Current Analyst Ratings Breakdown

Latest IBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$5.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iBio, Inc. stock logo
IBIO
iBio
$375K45.01N/AN/A$1.41 per share0.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iBio, Inc. stock logo
IBIO
iBio
-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iBio, Inc. stock logo
IBIO
iBio
0.05
1.76
1.76

Institutional Ownership

CompanyInstitutional Ownership
iBio, Inc. stock logo
IBIO
iBio
7.90%

Insider Ownership

CompanyInsider Ownership
iBio, Inc. stock logo
IBIO
iBio
0.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
iBio, Inc. stock logo
IBIO
iBio
10019.66 million9.82 millionN/A

Recent News About These Companies

Brokers Set Expectations for iBio FY2025 Earnings
September 1 at 2:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30306236
Analysts Offer Predictions for iBio Q1 Earnings
August 30, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30303414
iBio Announces Closing of $50 Million Public Offering
August 25, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/25/3138341/0/en/ibio-announces-closing-of-50-million-public-offering.html
iBio Announces $50 Million Public Offering Agreement
August 22, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/ibio-announces-50-million-public-offering-agreement/ar-AA1KZcZL
iBio Announces Pricing of $50 Million Public Offering
August 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/19/3135662/0/en/ibio-announces-pricing-of-50-million-public-offering.html
iBio, Inc. Announces Launch of Underwritten Public Offering of Pre-Funded Warrants and Series G Warrants
August 18, 2025  |  quiverquant.comQ
iBio Announces Proposed Public Offering
August 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/18/3135292/0/en/ibio-announces-proposed-public-offering.html
Report details last year's biggest venture deals in Illinois life science companies
August 5, 2025  |  chicagobusiness.comC
iBio Faces Nasdaq Delisting Notice for Stock Price
August 1, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ibio-faces-nasdaq-delisting-notice-for-stock-price?utm_source=marketbeat.com&utm_medium=referral
Pharos IBio Co Ltd Share Price - Investing.com UK
June 30, 2025  |  uk.investing.comhttps://uk.investing.com/equities/pharos-ibio
iBio Announces Conference Call to Review Myostatin and Activin E Antibody Data and Reveal Third Target in AstralBio Collaboration on June 24 | Nasdaq
June 24, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/ibio-announces-conference-call-review-myostatin-and-activin-e-antibody-data-and-reveal
iBio Advances Obesity Care with Antibody Therapies
June 24, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ibio-advances-obesity-care-with-antibody-therapies?utm_source=marketbeat.com&utm_medium=referral
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
June 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/24/3104087/0/en/ibio-and-astralbio-unveil-obesity-program-with-novel-amylin-agonist-antibody-demonstrating-promising-in-vivo-results.html
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
June 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/23/3103838/0/en/ibio-presents-next-generation-obesity-and-cardiometabolic-pipeline-candidates-on-june-24-conference-call.html
iBio Extends Promissory Note Maturity to 2026
June 18, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ibio-extends-promissory-note-maturity-to-2026?utm_source=marketbeat.com&utm_medium=referral
Ibio nominates IBIO-610 as obesity development candidate
June 18, 2025  |  bioworld.comB
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
June 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/16/3099692/0/en/ibio-initiates-non-human-primate-study-of-first-in-class-activin-e-antibody-following-positive-preclinical-data-demonstrating-prevention-in-weight-regain-after-glp-1-treatment.html
Minister hails ‘exciting’ degree where students spend two years working in industry
May 29, 2025  |  irishtimes.comhttps://www.irishtimes.com/ireland/education/2025/05/29/minister-hails-exciting-new-degree-where-students-spend-two-years-working-in-industry/
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
May 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/ibio-first-class-activin-e-120000623.html
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
May 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/05/3074000/0/en/ibio-s-first-in-class-activin-e-antibody-achieves-26-fat-reduction-without-muscle-loss-and-shows-synergy-with-glp-1s-in-preclinical-model.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

iBio stock logo

iBio NYSE:IBIO

$0.86 +0.05 (+5.88%)
Closing price 04:00 PM Eastern
Extended Trading
$0.84 -0.02 (-1.96%)
As of 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas